Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05252910
Other study ID # 2021SPEC-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date March 4, 2022

Study information

Verified date March 2022
Source Pharm-Olam, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive locally authorized or licensed COVID-19 vaccines. Approximately 1,000 participants will be enrolled. Plasma and peripheral blood mononuclear cell samples will be obtained either by venipuncture, or by leukapheresis. Serum, RNA, and DNA samples will be obtained by venipuncture. Specimens for mucosal antibody assessments will be collected by nasal swabbing. Biological specimens will be collected from study participants at Baseline prior to the COVID-19 vaccine dose and at timepoints aligned with the study participant's vaccination schedule for a period of up to 1 year following receipt of the initial COVID-19 vaccination.


Description:

This specimen collection study will generate a bank of biological specimens/samples and associated meta data from severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) naïve adults and adolescent participants ≥12 years old who will receive authorized or licensed Coronavirus Disease 2019 (COVID-19) vaccine as a matter of care. The samples may be used to determine immunological responses and microbiologic factors, to develop novel assays, diagnostic tests, therapeutic agents, and vaccines. Vaccines received by study participants will be only those supported and approved for use by the United States Government, and authorized or licensed for use in the country in which the participant is enrolled. Participants will be receiving COVID-19 vaccine as a matter of standard preventive medical care, and not as a research activity. Participant screening and biological specimen collection will occur only after informed consent/assent. Participants may participate in all, or a part, of this study to provide biological specimens. Participants who are eligible for the study will be stratified into age groups: ≥12 to <18 years, ≥18 to ≤65 years, >65 years of age. Approximately 1,000 participants will be enrolled in this study. Biological specimens will be collected from each participant for up to 1 year following receipt of their initial COVID-19 vaccination. Additional participants may be enrolled for up to 2 additional years. Enrollment dynamics will be actively monitored across all sites, and efforts will be made to balance enrollment by sex, age group, and type of vaccine received. Testing of blood samples obtained from study participants at screening will be performed on an ongoing basis to assess for evidence of prior COVID-19 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serostatus of participants across the program will be actively monitored to target an enrollment of at least 75% seronegative participants for both adult as well as adolescent participants. Demographic data, height and weight, vaccination details, major past medical history, and comorbidities will be collected at baseline from study participants. Concomitant medications, significant intercurrent medical events, and unanticipated adverse events or problems posing risks to study subjects will be recorded from enrollment through the end of the study for all participants. There is no analysis plan or primary or secondary endpoints for this specimen collection study. The study will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of generating a repository of serial blood (collected by phlebotomy and leukapheresis) and nasal swab specimens from severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who have received authorized or licensed COVID-19 vaccines. Samples will be identified only by subject identification number.


Recruitment information / eligibility

Status Terminated
Enrollment 33
Est. completion date March 4, 2022
Est. primary completion date March 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Male or non-pregnant (by participant report) female adults (=18 years or older) or adolescents (=12 years old and <18 years old) in generally good health, who will receive a locally licensed or authorized COVID-19 vaccine, development of which was supported by the United States Government, as part of standard preventive medical care. - Able to understand and sign the Informed Consent Form (for adolescent participants informed consent form from parent and participant assent). - Participants with some medical conditions that might otherwise disqualify them from routine blood or blood component donations, such as HIV/AIDS, diabetes mellitus, etc., can participate if their conditions are stable, well-controlled, have had no change in clinical status or medication for at least 6 months, and whose participation in the protocol would not present excess risk to the participant as judged by the Investigator. - Willing to comply with study procedures and schedule for sample collections. - Available for follow-up visits over the next year. For individuals willing to undergo leukapheresis procedure(s), Adults =18 years, and adolescents =12-17 years must meet the following minimum criteria: - Weight =110 pounds/50 kg - Platelet count >150×109/L - Adequate bilateral antecubital veins to allow for 2 peripheral vein access points. - At least 2 weeks since any previous blood product donation. Exclusion Criteria: - Prior receipt of any COVID-19 vaccine. - Anemia at screening, or history of anemia caused by chronic therapies or congenital/genetic conditions (e.g., thalassemia) per participant/parent report. Individuals with histories of anemias that have been remedied with treatment (e.g., parasitism, B12, iron deficiency) are allowed. - Have a history of intravenous drug abuse. - Have a history of sickle cell disease per participant/parent report - Have a history of poorly controlled or clinically significant heart, lung, kidney disease, per participant/parent report and Investigator assessment. - Have a history of Hepatitis B or C, per participant/parent report. Participants with resolved Hepatitis B or C, or those with no apparent clinical manifestations of these infections, may participate. - Have a contraindication to phlebotomy (i.e., evidence of cellulitis or abscess; venous thrombosis on palpation; presence of hematoma; presence of vascular shunt, graft, or access device; anti-coagulation therapy; history of bleeding diathesis; or clinically significant thrombocytopenia (platelet count <150×109/L) as assessed by Investigator, participant/parent report, or screening platelet count. - Have a history of untreated, unresolved, or recurrent malaria during the preceding 12 months per participant/parent report. - Have donated blood in the past 8 weeks. - Have planned surgery in the next 8 weeks. - Is breast feeding, pregnant, or may be pregnant, per participant report. - Are currently participating or are planning to participate in any clinical trial, including a COVID-19 vaccine trial or COVID-19 therapeutic trial. - Any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study. - Any condition that in the judgement of the Investigator precludes participation because it could adversely affect participant safety or data integrity.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Colombia Bluecare Salud SAS Bogotá Columbia
Colombia Servimed SAS Bucaramanga Santander
Colombia Clinisalud Envigado Antioquia
Guadeloupe University Hospital Center of Guadeloupe Les Abymes
India Government Medical College & Hospital Aurangabad Maharashtra
India Peerless Hospitex Hospital Kolkata West Bengal
India Govt. Medical College Nagpur Maharashtra
India Grant Medical Foundation Ruby Hall Clinic Pune Maharashtra
India Unity Hospital Surat Gujarat
India GMERS Medical College & Hospital Vadodara Gujarat
India Andhra Medical College Visakhapatnam Andhra Pradesh
Mexico Icaro Investigaciones en Medicina SA de CV Chihuahua
Puerto Rico CAIMED Center at the Ponce School of Medicine Ponce
South Africa Worthwhile Clinical Trials Benoni Gauteng
South Africa REIMED Wilhase Practice Boksburg Gauteng
South Africa Langeberg Clinical Trials Cape Town Western Cape
South Africa Task Applied Science Cape Town Western Cape
South Africa DR P J Sebastian Clinical Research Centre Durban KwaZulu-Natal
South Africa Synapta Clinical Research Centre Durban KwaZulu-Natal
South Africa Clinresco Centres Kempton Park Gauteng
South Africa Aurum Klerksdorp CRS Klerksdorp North-West
South Africa Clinical Research Institute of South Africa (CRISA) KwaDukuza Kwazulu-Natal
South Africa Larisha Pillay-Ramaya Pretoria Gauteng
South Africa Muhammed Ameen Fulat Pretoria Gauteng
South Africa The Aurum Institute, Rustenburg Clinical Research Site Rustenburg North-West
South Africa Johan Geldenhuys Vereeniging Gauteng
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Pan American Clinical Research LLC Brownsville Texas
United States Meharry Medical College/Meharry Medical Center Nashville Tennessee
United States University of Nebraska Medical Center Omaha Nebraska
United States Clinical Trials of Texas, LLC San Antonio Texas
United States SUNY Upstate Medical University Syracuse New York

Sponsors (2)

Lead Sponsor Collaborator
Pharm-Olam, LLC Biomedical Advanced Research and Development Authority

Countries where clinical trial is conducted

United States,  Colombia,  Guadeloupe,  India,  Mexico,  Puerto Rico,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Specimen Collection This study is designed to collect biological specimens/samples to generate a biological specimen repository of samples from severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) naïve adults and adolescent participants =12 years old who will be receiving, as a matter of care, locally authorized or licensed Coronavirus Disease 2019 (COVID-19) vaccines whose development has been supported by the US Government. Specimens collected with associated metadata will be shared with the US Government and stakeholders. 12 months (1 year)
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure